Comment
. 2005 Nov 1;23(31):8124-5; author reply 8125-6.
doi: 10.1200/JCO.2005.03.2458.
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
- PMID: 16258115
- DOI: 10.1200/JCO.2005.03.2458
Item in Clipboard
Comment
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
J Clin Oncol.
.
No abstract available
Comment on
-
Prostate cancer chemotherapy: emerging from the shadows.J Clin Oncol. 2005 May 20;23(15):3302-3. doi: 10.1200/JCO.2005.11.933. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738529 No abstract available.
-
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738542 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
